US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Lycia Therapeutics

30.00

+12.0066.67%

Post-market: 26.50-3.5000-11.67%19:59 EDT

Volume:2.29M

Turnover:63.26M

Market Cap:1.56B

PE:- -

High:36.49

Open:28.55

Low:22.19

Close:18.00

52wk High:36.49

52wk Low:22.19

Shares:52.09M

Float Shares:14.70M

Volume Ratio:- -

T/O Rate:15.56%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:-11.83

PE(LYR):- -

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Lycia Therapeutics

Exchange:

NASDAQ

Establishment Date:

2019

Employees:

31

Office Location:

400 East Jamie Court,Suite 200,South San Francisco,California,United States

Website:

http://www.lyciatx.com

Zip Code:

94080

Phone:

Fax:

- -

Introduction:

Lycia Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics designed to degrade disease-causing extracellular proteins, initially targeting autoimmune, inflammatory and allergic diseases. Its proprietary LYTAC (Lysosomal Targeting Chimera) platform is designed to enable deep and durable depletion of extracellular proteins, including through cataLYTAC degraders that repeatedly eliminate target proteins. Its pipeline includes LCA-0061 and LCA-0062, which target immunoglobulin E (IgE) for food allergy and other allergic diseases, and LCA-0321, which targets thyroid-stimulating hormone receptor autoantibodies for Graves' disease. The company is headquartered in South San Francisco, California.

Directors

Name

Position

Aetna Wun Trombley

Director,Chief Executive Officer and President

Jane Pritchett Henderson

Independent Director

Laurent Fischer

Independent Director

William J. Rieflin

Chair of the Board and Independent Director

Shareholders

Name

Position

Aetna Wun Trombley

Director,Chief Executive Officer and President

Amy Bachrodt

Chief Financial Officer

Chin Lee

Chief Medical Officer

Sofia Touami

Chief Business Officer

Steve Staben

Chief Scientific Officer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/LYCA/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LYCA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LYCA\",,,,,undefined,":{"symbol":"LYCA","market":"US","secType":"STK","nameCN":"Lycia Therapeutics","latestPrice":30,"timestamp":1792785600000,"preClose":18,"halted":0,"volume":2287202,"hourTrading":{"tag":"盘后","latestPrice":26.5,"preClose":30,"latestTime":"19:59 EDT","volume":21598,"amount":605931.297,"timestamp":1792799969687,"change":-3.5,"changeRate":-0.116667,"amplitude":0.116667},"delay":0,"changeRate":0.6666666666666666,"floatShares":14700000,"shares":52094559,"eps":0,"marketStatus":"Market Closed","change":12,"latestTime":"10-23 16:00:00 EDT","open":28.55,"high":36.4931,"low":22.19,"amount":63259421.47999,"amplitude":0.794617,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1793001600000},"marketStatusCode":7,"adr":0,"listingDate":1792728000000,"exchange":"NASDAQ","adjPreClose":18,"postHourTrading":{"tag":"盘后","latestPrice":26.5,"preClose":30,"latestTime":"19:59 EDT","volume":21598,"amount":605931.297,"timestamp":1792799969687,"change":-3.5,"changeRate":-0.116667,"amplitude":0.116667},"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LYCA\",,,,,undefined,":{"symbol":"LYCA","floatShares":14700000,"roa":"--","roe":"--","lyrEps":0,"shares":52094559,"dividePrice":0,"high":36.4931,"amplitude":0.794617,"preClose":18,"low":22.19,"week52Low":22.19,"pbRate":"-11.83","psRate":"352.39","week52High":36.4931,"institutionHeld":0,"latestPrice":30,"eps":0,"divideRate":0,"volume":2287202,"delay":0,"ttmEps":0,"open":28.55,"prevYearClose":18,"prevWeekClose":18,"prevMonthClose":18,"prevQuarterClose":18,"fiveDayClose":18,"twentyDayClose":18,"sixtyDayClose":18},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LYCA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LYCA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LYCA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":659118750,"yearFounded":2019,"employeeNum":31,"address":"400 East Jamie Court,Suite 200,South San Francisco,California,United States","zipCode":"94080","officePhone":"(650) 392-3357"},"stockCompanyDetail":{"websiteUrl":"http://www.lyciatx.com","stockEarnings":[{"period":"1week","weight":0.6667},{"period":"ytd","weight":0.6667}],"compareEarnings":[{"period":"1week","weight":-0.0043},{"period":"1month","weight":-0.0102},{"period":"3month","weight":0.0285},{"period":"6month","weight":0.0645},{"period":"1year","weight":0.1313},{"period":"ytd","weight":0.1145}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Lycia Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics designed to degrade disease-causing extracellular proteins, initially targeting autoimmune, inflammatory and allergic diseases. Its proprietary LYTAC (Lysosomal Targeting Chimera) platform is designed to enable deep and durable depletion of extracellular proteins, including through cataLYTAC degraders that repeatedly eliminate target proteins. Its pipeline includes LCA-0061 and LCA-0062, which target immunoglobulin E (IgE) for food allergy and other allergic diseases, and LCA-0321, which targets thyroid-stimulating hormone receptor autoantibodies for Graves' disease. The company is headquartered in South San Francisco, California.","exchange":"NASDAQ","name":"Lycia Therapeutics","nameEN":"Lycia Therapeutics"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"LYCA\",market:\"US\",,,undefined,":{"directors":[{"name":"Aetna Wun Trombley","position":"Director,Chief Executive Officer and President"},{"name":"Jane Pritchett Henderson","position":"Independent Director"},{"name":"Laurent Fischer","position":"Independent Director"},{"name":"William J. Rieflin","position":"Chair of the Board and Independent Director"}],"executives":[{"name":"Aetna Wun Trombley","position":"Director,Chief Executive Officer and President"},{"name":"Amy Bachrodt","position":"Chief Financial Officer"},{"name":"Chin Lee","position":"Chief Medical Officer"},{"name":"Sofia Touami","position":"Chief Business Officer"},{"name":"Steve Staben","position":"Chief Scientific Officer"}]}}}